Gary D. Steinberg, MD, a nationally recognized specialist in the surgical management of bladder cancer, has been named director of the Goldstein Urology Bladder Cancer Program at NYU Langone Health. His recruitment enhances the team of clinicians and scientists already assembled within the Department of Urology and NYU Langone Health’s Perlmutter Cancer Center who focus on this form of cancer.

Dr. Steinberg, also named professor in the Department of Urology at NYU School of Medicine, has dedicated his career to the advancement of bladder cancer education, research, and treatment. He joins NYU Langone from the University of Chicago, where he most recently served as the Bruce and Beth White Family Professor of Urologic Oncology and director of Urologic Oncology.

“We are thrilled to welcome Dr. Steinberg to the Department of Urology and the NYU Langone Health faculty,” says Herbert Lepor, MD, the Martin Spatz Chair of Urology. “His commitment to improving surgical outcomes and robust portfolio of clinical trials aligns with our mission to provide the best, personalized care for those diagnosed with bladder cancer.”

A national authority in the surgical treatment of bladder cancer and urinary tract reconstruction, Dr. Steinberg has performed more than 2,000 radical cystectomies. He is well-known for his specialization in re-operative procedures for patients whose prior surgery failed, using novel techniques to restore normal bladder function.

Additionally, Dr. Steinberg is a pioneer in the use of blue light cystoscopy to detect and remove early stage bladder cancer. He has made significant contributions to our understanding of both non-muscle invasive and invasive bladder cancer, and serves as the principle investigator on numerous clinical trials, working to identify new molecular biomarkers to detect the disease.

NYU Langone’s Bladder Cancer Program, part of the Perlmutter Cancer Center, offers patients the most sophisticated treatments and has one of the largest bladder cancer clinical trials programs in the United States. The multidisciplinary team of urologic oncologists, medical oncologists, radiologists, radiation oncologists, and pathologists work together to evaluate and determine the best treatment option for each patient.

About Dr. Steinberg

An alumnus of the University of Chicago Medical School, Dr. Steinberg completed his internship, residency, and fellowship at the Johns Hopkins University in Baltimore, Maryland. While at Johns Hopkins, he was an American Cancer Society clinical fellow in urologic oncology and went on to complete additional training in the surgical management of bladder cancer.

A prolific researcher, Dr. Steinberg has published hundreds of peer-reviewed articles and textbook chapters. He continues to present at national and international meetings, and serves as a reviewer on a number of editorial boards for urology and urologic Oncology journals. He serve as chairperson of the Bladder Cancer Advocacy Network scientific advisory board, along as an executive member of the Bladder Cancer Research Network.

“I’m honored to join a team of devoted clinicians, scientists, and staff, working tirelessly to improve the lives of our patients,” says Dr. Steinberg. “As we look towards the future, we’ll bring our expertise in basic and translational research to the bedside, furthering our ability to provide personalized therapy to all patients across the health system with bladder cancer.”

Media Inquiries

Rob Magyar
Phone: 212-404-3591
robert.magyar@nyulangone.org